IL-13 Activators
Interleukin-13 (IL-13) is a cytokine that plays a central role in regulating immune responses, inflammation, and tissue remodeling. It belongs to the family of interleukin-4 (IL-4)-related cytokines and shares structural and functional similarities with IL-4. IL-13 exerts its biological effects by binding to its specific cell surface receptor complex, composed of the IL-13 receptor alpha 1 (IL-13Rα1) and the IL-4 receptor alpha (IL-4Rα) subunits. Upon ligand binding, IL-13 triggers downstream signaling cascades that modulate various cellular processes, including immune cell activation, differentiation, and cytokine production. One of the primary functions of IL-13 is its involvement in allergic responses and the pathogenesis of asthma, where it promotes airway inflammation, mucus hypersecretion, and tissue fibrosis. Additionally, IL-13 plays a role in mediating anti-inflammatory and tissue repair processes, particularly in the context of chronic inflammatory diseases and tissue remodeling.
Activation of IL-13 signaling involves complex mechanisms that initiate intracellular signaling cascades upon ligand binding to its receptor complex. Upon IL-13 binding to the IL-13Rα1/IL-4Rα receptor complex, receptor dimerization occurs, leading to the recruitment and activation of cytoplasmic signaling molecules, such as Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) proteins. Subsequently, activated JAKs phosphorylate tyrosine residues on the receptor cytoplasmic tails, providing docking sites for STAT proteins. Phosphorylated STAT proteins then translocate to the nucleus, where they regulate the transcription of target genes involved in various cellular processes, including inflammation, immune responses, and tissue remodeling. Additionally, IL-13 signaling can intersect with other signaling pathways, such as those mediated by mitogen-activated protein kinases (MAPKs) and phosphoinositide 3-kinase (PI3K), further expanding its regulatory effects on cellular physiology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a pyridinyl imidazole, enhances IL-13 functional activity by positively influencing the p38 MAPK pathway. Acting as a selective inhibitor of p38α and p38β isoforms, it hampers the negative regulation of IL-13 signaling, resulting in amplified downstream responses. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a fungal metabolite, enhances IL-13 activation by targeting the PI3K/AKT pathway. It irreversibly inhibits PI3K, disrupting downstream AKT phosphorylation. This disruption leads to sustained IL-13 signaling, fostering increased cellular responses and functional activity. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $156.00 $339.00 | 59 | |
JAK Inhibitor I, a small molecule, indirectly enhances IL-13 activity by inhibiting the JAK/STAT pathway. By specifically blocking JAK activation, it prevents the negative regulation of IL-13-induced gene expression, resulting in an augmentation of IL-13 functional activity. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
IKK-2 Inhibitor IV (TPCA-1) enhances IL-13 activation by influencing the NF-κB pathway. By targeting IKK-2, it impedes IκBα phosphorylation and degradation, leading to the accumulation of NF-κB in the cytoplasm and subsequent potentiation of IL-13-induced cellular responses. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a potent PI3K inhibitor, enhances IL-13 functional activity by disrupting the PI3K/AKT pathway. It prevents the phosphorylation of AKT, hindering the negative regulation of IL-13 signaling. This interference results in increased IL-13-induced cellular responses and functional activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a selective JNK inhibitor, indirectly enhances IL-13 activity by targeting the JNK pathway. By inhibiting JNK activation, it prevents the negative regulation of IL-13-induced gene expression, leading to amplified downstream responses and increased IL-13 functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, enhances IL-13 activation by influencing the MAPK pathway. It impedes the phosphorylation of ERK1/2, disrupting the negative regulation of IL-13 signaling. This disruption results in increased IL-13-induced cellular responses and functional activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082, an NF-κB inhibitor, enhances IL-13 functional activity by modulating the NF-κB pathway. By preventing the phosphorylation and degradation of IκBα, it facilitates the nuclear translocation of NF-κB, amplifying IL-13-induced gene expression and cellular responses. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542, a TGF-β receptor inhibitor, indirectly enhances IL-13 activity by influencing the TGF-β pathway. By inhibiting TGF-β receptor activation, it disrupts the negative regulation of IL-13-induced gene expression, leading to amplified downstream responses and increased IL-13 functional activity. | ||||||
PI 3-Kγ Inhibitor | 648450-29-7 | sc-203191 | 5 mg | $76.00 | ||
PI 3-Kγ Inhibitor (AS605240) enhances IL-13 functional activity by specifically targeting the PI3K/AKT pathway. By inhibiting PI3Kγ, it disrupts downstream AKT phosphorylation, hindering the negative regulation of IL-13 signaling and resulting in increased IL-13-induced cellular responses. | ||||||